Insider Selling: Emergent Biosolutions Inc (EBS) EVP Sells 1,898 Shares of Stock
Emergent Biosolutions Inc (NYSE:EBS) EVP Adam Havey sold 1,898 shares of the stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $49.50, for a total transaction of $93,951.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Emergent Biosolutions Inc (NYSE EBS) traded up $0.42 during trading hours on Friday, hitting $49.67. 357,269 shares of the company were exchanged, compared to its average volume of 382,653. The company has a current ratio of 4.85, a quick ratio of 3.42 and a debt-to-equity ratio of 0.01. Emergent Biosolutions Inc has a 1 year low of $27.94 and a 1 year high of $51.25. The company has a market cap of $2,437.61, a P/E ratio of 29.39, a price-to-earnings-growth ratio of 0.99 and a beta of 1.26.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.70 by $0.04. Emergent Biosolutions had a net margin of 14.73% and a return on equity of 13.66%. The firm had revenue of $193.80 million during the quarter, compared to the consensus estimate of $189.96 million. During the same quarter last year, the firm earned $0.74 EPS. The firm’s revenue for the quarter was up 27.8% compared to the same quarter last year. equities research analysts predict that Emergent Biosolutions Inc will post 2.27 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the stock. Xact Kapitalforvaltning AB bought a new position in shares of Emergent Biosolutions in the 4th quarter valued at about $265,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lifted its stake in Emergent Biosolutions by 73.1% in the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 22,500 shares of the biopharmaceutical company’s stock worth $1,046,000 after purchasing an additional 9,500 shares during the last quarter. MetLife Investment Advisors LLC bought a new stake in Emergent Biosolutions in the fourth quarter worth about $730,000. Municipal Employees Retirement System of Michigan lifted its stake in Emergent Biosolutions by 20.9% in the fourth quarter. Municipal Employees Retirement System of Michigan now owns 15,930 shares of the biopharmaceutical company’s stock worth $740,000 after purchasing an additional 2,750 shares during the last quarter. Finally, Clark Capital Management Group Inc. lifted its stake in Emergent Biosolutions by 40.1% in the fourth quarter. Clark Capital Management Group Inc. now owns 77,245 shares of the biopharmaceutical company’s stock worth $3,590,000 after purchasing an additional 22,103 shares during the last quarter. 78.23% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This report was posted by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2018/03/03/insider-selling-emergent-biosolutions-inc-ebs-evp-sells-1898-shares-of-stock.html.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.